Search clinical trials for: Lapatinib plus capecitabine

Total 7859 results

Tianjin Medical University Cancer Institute and...

Unknown

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) (HCC)

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.

Metastatic Renal Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Unknown

A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure

Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer

Hepatocellular Carcinoma

China
Zhejiang University

Recruiting

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma (CAPT)

Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

Hepatocellular Carcinoma

China
Hubei Cancer Hospital

Enrolling by invitation

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

NSCLC

China
Peking University Cancer Hospital & Institute
Peking University First Hospital; Shanxi Province Cancer Hospital; Peking University... and other collaborators

Completed

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Breast Cancer
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Second-line Treatment

China
Qianfoshan Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Immune Checkpoint Inhibition

China
Henan Cancer Hospital

Unknown

Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer

Advanced Gastric Cancer
GUO WEI

Completed

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

Osteosarcoma | Metastasis

China
Tianjin Medical University Cancer Institute and...
Zhejiang Cancer Hospital; Fudan University; Liaoning Tumor Hospital & Institute; Gansu Cancer Hospital

Unknown

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Soft Tissue Sarcoma, Adult, Stage II

China
Hebei Medical University Fourth Hospital

Recruiting

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Advanced Solid Tumor

China
Boehringer Ingelheim

Completed

Afatinib in Subjects With Kidney Dysfunction

Renal Insufficiency

Germany
The University of Tennessee, Knoxville
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Cherokee...

Completed

Implementing Prevention Plus for Childhood Overweight and Obesity in Food Secure and Insecure Families

Obesity | Childhood Obesity

United States
ResMed

Completed

Evaluation of ApneaLink Plus Scoring Capabilities

Sleep Apnea, Obstructive | Sleep Apnea, Central

Germany
Jiangxi Provincial Cancer Hospital

Recruiting

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Maintenance Therapy | High-Risk Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage

Gastric Cancer

China
Frederick R. Ueland, M.D.
National Cancer Institute (NCI)

Active, not recruiting

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Ovarian Cancer

United States
GlaxoSmithKline

Withdrawn

A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
GlaxoSmithKline

Completed

Lapatinib in Combination With Vinorelbine

Cancer

Turkey
Hebei Medical University

Completed

Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction (A-C)

Gastroesophageal Junction Adenocarcinoma

China
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline; Genentech, Inc.; Susan G. Komen Breast Cancer Foundation

Completed

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Breast Neoplasms

United States
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Lung Cancer | Non Small Cell Lung Cancer | Apatinib | Combination Chemotherapy

China
National Cancer Institute (NCI)

Completed

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular...

United States
Baylor Research Institute

Completed

Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

Metastatic Breast Cancer

United States
GlaxoSmithKline

Completed

Physician Liver Function Test (LFT) Monitoring for Tykerb Pts

Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Dasatinib Tablet

Leukemia, Myelogenous, Chronic

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) (OAIE)

Toxicity | Effect of Drug | Drug

China
Beijing Chest Hospital

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Non-small Cell Lung Cancer
Sun Yat-sen University

Recruiting

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Neoadjuvant Therapy | Apatinib | Carilizumab | Recurrent High-Grade Glioma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Relapsed Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

Colorectal Cancer

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Peking University People's Hospital
Peking University Shougang Hospital; Jiangsu HengRui Medicine Co.

Recruiting

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma (AIEO)

Effect of Drug | Toxicity, Drug

China
Sun Yat-sen University

Recruiting

Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma (C-couple)

Hepatocellular Carcinoma

China
Bukwang Pharmaceutical

Completed

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Gastric Cancer

Korea, Republic of
Beijing Tsinghua Chang Gung Hospital

Unknown

Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer

Hepatocellular Carcinoma
Fujian Cancer Hospital

Unknown

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens (ASGARD)

Advanced Metastatic Gastric Cancer
Guilin Medical University, China
Wuzhou Red Cross Hospital; Guangxi Naxishan Hospital; National Hospital of Guangxi...

Unknown

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Hepatocellular Carcinoma | Gastric Cancer

China
Tongji University

Unknown

The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy

Gastric Cancer

China
Novartis Pharmaceuticals

Recruiting

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Non-Small Cell Lung Carcinoma

India
Harbin Medical University

Recruiting

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Gastrointestinal Cancer | Immunotherapy | Targeted Therapy

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Sarcoma
Beijing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

HER-2 Negatived Gastric Cancer

China
Oslo University Hospital
The Research Council of Norway

Completed

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (MetAction)

Metastatic Cancer

Norway

Search clinical trials for: Lapatinib plus capecitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations